Molecular Staging

Transforming the Detection and Measurement of both Proteins and Nucleic Acids.

Contact us

About us

A strong demand has emerged in the life science industry for enabling technologies that can generate, analyze, and interpret genomics and proteomics data much more quickly and cost effectively than currently possible otherwise.

Molecular Staging Inc. (MSI), a life sciences company, is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.

These technologies are transformational because there has never before been a powerful molecular amplification method for proteins, or an effective whole genome amplification method…and because the technology platform combines unprecedented sensitivity and multiplexing advantages. MSI technologies, combined with sophisticated bioinformatics, broadly enable a wide range of products and services across multiple health care markets.

These products and services include: High-coverage protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins simultaneously.

Whole-genome amplification that allows DNA samples to be renewable resources, enabling researchers to return to them again and again for new tests or confirmatory diagnoses. Ultra-sensitive, multiplexed diagnostics that enable earlier detection of disease and reduced costs.

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy


We plan to develop and commercialize gene-based tests and immunoassays based on our core technology, Rolling Circle Amplification Technology (RCAT™), that can significantly improve the diagnosis of cancer, infectious diseases, neuropsychiatric disorders, auto-immune disorders, and other major disease states.

How It Works:

In order to diagnose a disease, physicians often need to look for things that are small in size such as cancer cells, virus particles, bacteria, mutated genes, etc. Physicians will use tests to find “target molecules” associated with these diseased cells or pathogens that indicate their presence. These target molecules might be the DNA of a bacteria or virus, a protein produced by cancerous cells, antibodies to a particular infection, or a particular sequence of a gene mutation. These target molecules are often present at very low levels, particularly in early stages of the disease when treatment might be the most beneficial. Physicians need a test that can easily locate the molecule of interest, and then “amplify” a signal from that molecule to indicate its detection.